Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

• This invention relates to pharmaceutical compositions utilizing compounds which have activity as estrogenic agents.
• This invention particularly relates to novel oral pharmaceutical compositions comprising one or more active pharmacological agents, such as TSE-424, ERA-923, raloxifene, tamoxifen, droloxifene, arzoxifene or CP 336156 and one or more pharmaceutically acceptable carriers or excipients.
• active pharmacological agents such as TSE-424, ERA-923, raloxifene, tamoxifen, droloxifene, arzoxifene or CP 336156 and one or more pharmaceutically acceptable carriers or excipients.
• EP 0 802 183 A1 and U.S. Pat. No. 5,780,497 describe substituted indole compounds of the formulae below:
• estrogenic agents including the treatment of bone loss, cardiovascular disease, maladies associated with or resulting from the proliferation or abnormal development of endometrial or endometrial-like tissues, and disease states or syndromes associated with estrogen deficiency.
• EP 0 802 184 A1 published Oct. 22, 1997, describes comparable uses for substituted indole compounds of the formulae below.
• U.S. Pat. No. 5,811,120 (Gibson, L. L. et al), titled “Solid orally administerable raloxifene hydrochloride pharmaceutical formulation” (Eli Lilly and Company), describes a composition and process for raloxifene hydrochloride tablets including a surfactant being a sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone (PVP), and a water soluble diluent which is a polyol or sugar. Raloxifene has low water solubility.
• the Gibson et al. patented composition claims the inclusion of PVP and a water-soluble diluent to achieve adequate solubility of raloxifene.
• U.S. Pat. No. 5,747,510 (Draper) teaches pharmaceutical formulations containing raloxifene in a dose range of from about 55 to about 150 mg.
• U.S. Pat. No. 5,747,510 (Gibson et al.) provides raloxifene formulations utilizing a surfactant, polyvinylpyrrolidone and a water soluble diluent, particularly those in which the surfactant is a sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester.
• U.S. Pat. Nos. 5,332,727 and 5,480,652 describe the use of antioxidants such as ascorbic acid in a solid pharmaceutical composition to stabilize the drug.
• the stabilizers added to the formulation include NaHCO 3 and PVP in addition to ascorbic acid and are not added to the formulation for an antioxidant effect per se.
• the antioxidant In the case of ibuprofen, the antioxidant must be in intimate contact with the active drug agent prior to its incorporation into the formulation in order to achieve its protective effect. This effect is only needed in the presence of alkaline carbonates in these effervescent formulations.
• WO 96/21656 (Cameron et al.) teaches novel compounds, including CP 336156, and uses for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.
• the present invention provides for orally administrable preparations that optimize the stability and enhance the dissolution of poorly soluble pharmaceutical agents, including estrogenic agents.
• Various formulations have been used to produce rapid dissolution of poorly soluble drugs, such as solubilization form (e.g. softgel capsules) or a high-energy form (e.g. solid dispersions). These techniques use specialized equipment and/or processes.
• the present invention provides pharmaceutically useful compositions which produce a rapid dissolution of poorly soluble drugs from a pharmaceutical solid dosage formulation via commonly used components and processes.
• This invention comprises novel pharmaceutical carrier or excipient systems useful in the formulation of solid oral dosage forms for poorly soluble pharmacological agents, including estrogenic pharmacological agents including, but not limited to, those in the art known as TSE-424, ERA-923, raloxifene, tamoxifen, droloxifene, and arzoxifene, as well as their analogs and pharmaceutically acceptable salts.
• estrogenic pharmacological agents including, but not limited to, those in the art known as TSE-424, ERA-923, raloxifene, tamoxifen, droloxifene, and arzoxifene, as well as their analogs and pharmaceutically acceptable salts.
• carrier or excipient systems comprise:
• a filler and disintegrant component comprising from about 5% to about 82% by weight (wght) of the total formulation, preferably between about 30% and about 80% of the formulation, of which from about 4% to about 40% by weight of the total formulation comprises one or more pharmaceutically acceptable disintegrants; and
• a lubricant comprising from about 0.2% to about 10% of the composition (wght), such as selected from the group of magnesium stearate or other metallic stearates (e.g. calcium stearate or zinc stearate), fatty acid esters (e.g. sodium stearyl fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oil, parrafins, hydrogenated vegetable oils, leucine, polyethylene glycols, metallic lauryl sulfates and sodium chloride.
• the composition such as selected from the group of magnesium stearate or other metallic stearates (e.g. calcium stearate or zinc stearate), fatty acid esters (e.g. sodium stearyl fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oil, parrafins, hydrogenated vegetable oils, leucine,
• the percentages listed above for the filler and disintegrant component and lubricant are percentages each will comprise of a final pharmaceutical composition.
• the remainder of the final composition will be comprised of the active pharmacological agent(s) and a pharmaceutically acceptable surface covering, such as a coating or capsule, as described herein.
• the active pharmacological agent(s) will comprise from about 0.5% to about 20%, by weight, of the final composition, more preferably from about 1% to about 5%, and the coating or capsule will comprise up to about 8%, by weight, of the formulation.
• the carrier or excipient system would comprise:
• the carrier or excipient systems or compositions herein may also optionally utilize pharmaceutically acceptable wetting agents, glidants and antioxidants.
• Such systems or compositions comprise:
• a filler and disintegrant component comprising from about 5% to about 82% by weight (wght) of the total formulation, preferably between about 30% and about 80% of the formulation, of which from about 4% to about 40% by weight of the total formulation comprises one or more pharmaceutically acceptable disintegrants;
• a wetting agent comprising from about 0.2 to about 5% of the composition (wght), such as selected from the group of sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, sugar esters of fatty acids and glycerides of fatty acids;
• a lubricant comprising from about 0.2% to about 10% of the composition (wght), such as selected from the group of magnesium stearate or other metallic stearates (e.g. calcium stearate or zinc stearate), fatty acid esters (e.g. sodium stearyl fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oil, parrafins, hydrogenated vegetable oils, leucine, polyethylene glycols, metallic lauryl sulfates and sodium chloride; and
• wght such as selected from the group of magnesium stearate or other metallic stearates (e.g. calcium stearate or zinc stearate), fatty acid esters (e.g. sodium stearyl fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oil, parrafins, hydrogenated vegetable oils,
• a glidant comprising from about 0.1% to about 10% (wght) of the composition, the glidant selected from those known in the art, including from the group of silicon dioxide, talc, metallic stearates, calcium silicate, or metallic lauryl sulfates.
• This invention also comprises solid oral formulations or compositions of a pharmaceutically effective dose of an active pharmacological compound, or a pharmaceutically acceptable salt thereof, and a carrier or excipient system of this invention, as described above.
• active pharmacological agents for use with these carrier or excipients systems are non-steroidal estrogenic agents or tissues selective estrogenic agents. Examples of these compounds include, but are not limited to TSE-424, ERA-923, raloxifene, tamoxifen, droloxifene, arzoxifene or CP 336156, or a pharmaceutically acceptable salt of these compounds.
• compositions described herein may be used in an uncoated or non-encapsulated solid form, preferably the final compositions are coated or encapsulated.
• the pharmacological compositions may be optionally coated with a film coating, preferably comprising from about 0.3% to about 8% by weight of the overall composition.
• Film coatings useful with the present formulations are known in the art and generally consist of a polymer (usually a cellulosic type of polymer), a colorant and a plasticizer. Additional ingredients such as wetting agents, sugars, flavors, oils and lubricants may be included in film coating formulations to impart certain characteristics to the film coat.
• the compositions and formulations herein may also be combined and processed as a solid, then placed in a capsule form, such as a gelatin capsule.
• the filler component listed above may utilize the filler or binder components known in the art for solid oral formulations.
• Pharmaceutically acceptable fillers or binding agents selected from those known in the art including, but not limited to, lactose, microcrystalline cellulose, sucrose, mannitol, calcium phosphate, calcium carbonate, powdered cellulose, maltodextrin, sorbitol, starch, or xylitol.
• disintegrant agents may be selected from those known in the art, including pregelatinized starch and sodium starch glycolate.
• Other useful disintegrants include croscarmellose sodium, crospovidone, starch, alginic acid, sodium alginate, clays (e.g.
• veegum or xanthan gum cellulose floc
• ion exchange resins or effervescent systems, such as those utilizing food acids (such as citric acid, tartaric acid, malic acid, fumaric acid, lactic acid, adipic acid, ascorbic acid, aspartic acid, erythorbic acid, glutamic acid, and succinic acid) and an alkaline carbonate component (such as sodium bicarbonate, calcium carbonate, magnesium carbonate, potassium carbonate, ammonium carbonate, etc.).
• the disintegrant(s) useful herein will comprise from about 4% to about 40% of the composition by weight, preferably from about 15% to about 35%, more preferably from about 20% to about 35%.
• Some components may have multiple functions in the formulations of this invention, acting e.g. as both a filler and a disintegrant, such a component may be referred to as a filler disintegrant and its function in a specific formulation may be singular even though its properties may allow multiple functionality.
• the pharmaceutical formulations and carrier or excipient systems herein preferably also contain an antioxidant or a mixture of antioxidants, most preferably ascorbic acid.
• Other antioxidants which may be used include sodium ascorbate and ascorbyl palmitate, preferably in conjunction with an amount of ascorbic acid.
• a preferable range for the antioxidant(s) is from about 0.5% to about 15% by weight, most preferably from about 0.5% to about 5% by weight.
• compositions comprising pharmaceutical carriers or excipients, as described above, and a pharmaceutically effective amount of a compound of the formulae I or II, below:
• Z is a moiety selected from the group of:
• R 1 is selected from H, OH or the C 1 -C 12 esters (straight chain or branched) or C 1 -C 12 (straight chain or branched or cyclic) alkyl ethers thereof, benzyloxy, or halogens; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether;
• R 2 , R 3 , R 5 , and R 6 are independently selected from H, OH or the C 1 -C 12 esters (straight chain or branched) or C 1 -C 12 alkyl ethers (straight chain or branched or cyclic) thereof, halogens, or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether, cyano, C 1 -C 6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH;
• R 4 is selected from H, OH or the C 1 -C 2 esters (straight chain or branched) or C 1 -C 2 alkyl ethers (straight chain or branched or cyclic) thereof, benzyloxy, halogens, or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether, cyano, C 1 -C 6 alkyl (straight chain or branched), or trifluoromethyl;
• X is selected from H, C 1 -C 6 alkyl, cyano, nitro, trifluoromethyl, halogen;
• n 2 or 3;
• Y is selected from:
• R 7 and R 8 are independently selected from the group of H, C 1 -C 6 alkyl, or phenyl optionally substituted by CN, C 1 -C 6 alkyl (straight chain or branched), C 1 -C 6 alkoxy (straight chain or branched), halogen, —OH, —CF 3 , or —OCF 3 ;
• compositions comprising pharmaceutical carriers or excipients, as described above, and a pharmaceutically effective amount of raloxifene, having the formula:
• raloxifene or its analogs which are described in U.S. Pat. No. 4,133,814 (Jones et al.—issued Jan. 9, 1979) and U.S. Pat. No. 4,418,068 (Jones—issued Nov. 29, 1983), both of which are incorporated herein by reference.
• a pharmaceutical composition comprising a carrier or excipient system, as described above, and a pharmaceutically effective amount of raloxifene or a pharmaceutically acceptable salt thereof.
• the salt is a hydrochloride salt of raloxifene.
• compositions of this invention utilize as an active ingredient a pharmaceutically effective amount of Benzo[b]thiophene-6-ol,2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-(9CI), also known as Arzoxifene or LY 353381 (Registry No. 182133-25-1), or an analog or pharmaceutically acceptable salt form thereof, having the structure:
• Arzoxifene and its analogs are disclosed in U.S. Pat. No. 5,510,358 (Palkowitz) and U.S. Pat. No. 5,919,800 (Palkowitz), which are incorporated herein by reference for their teaching of the synthesis of these compounds and representative salt forms thereof.
• Dosage forms of Arzoxifene and its analogs, or salt forms thereof are preferably administered at a daily dosage level of from about 5 mg to about 600 mg.
• a preferred daily dosage may be from about 15 mg to about 80 mg in a single dose administration or in divided doses over a daily regimen.
• Another embodiment of this invention comprises pharmaceutical formulations utilizing in conjunction with the carrier or excipient systems herein a pharmaceutically effective amount of the compound 2-Naphthalenol,5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-(5R,6S)-(2S,3S)-2,3-dihydroxybutanedioate(1:1 )(salt)(9Cl), also known as CP 336156 (Registry No. 190791-29-8), having the structure:
• CP 336156 or analogs of CP 336156, or the pharmaceutically acceptable salts of CP 336156 or its analogs.
• These compounds are disclosed in WO 96/21656 (Cameron et al.), which is incorporated herein by reference to demonstrate the preparation and identity of these compounds.
• a pharmaceutically effective dose of these compounds may be delivered at a concentration of from about 0.1 mg to about 50 mg per day, preferably at a daily dosage of from about 0.5 mg to about 25 mg.
• substituted indole compounds used in the formulations of this invention are those having the general structures I or II, above, wherein:
• R 1 is selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, benzyloxy, or halogen;
• R 2 , R 3 , R 5 , and R 6 are independently selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, halogen, cyano, C 1 -C 6 alkyl, or trihalomethyl, preferably trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH;
• R 4 is selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, benzyloxy, halogen, cyano, C 1 -C 6 alkyl, or trihalomethyl;
• X is selected from H, C 1 -C 6 alkyl, cyano, nitro, trifluoromethyl, halogen;
• Y is the moiety
• R 7 and R 8 are selected independently from H, C 1 -C 6 alkyl, or combined by —(CH 2 )p—, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, —CO 2 H, —CN, —CONH(C 1 -C 4 ), —NH 3 , C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, —NHSO 2 (C 1 -C 4 ), —NHCO(C 1 -
• the rings formed by a concatenated R 7 and R 8 may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
• indole compounds of the present invention are those having the structural formulas I or II, above, wherein R 1 is OH; R 2 -R 6 are as defined above; X is selected from the group of Cl, NO 2 , CN, CF 3 , or CH 3 ; and Y is the moiety
• R 7 and R 8 are concatenated together as —(CH 2 ) r —, wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, —CO 2 H, —CN, —CONH(C 1 -C 4 )alkyl, —NH 2 , C 1 -C 4 alkylamino, di(C 1 -C 4 )alkylamino, —NHSO 2 (C 1 -C 4 )alkyl, —NHCO(C 1 -C 4 )
• R 7 and R 8 are concatenated together as —(CH 2 )p—, wherein p is an integer of from 2 to 6, preferably 4 to 6, the ring so formed is optionally substituted with 1-3 substituents selected from a group containing C 1 -C 3 alkyl, trifluoromethyl, halogen, hydrogen, phenyl, nitro, —CN.
• the invention includes sulfate, sulfamates and sulfate esters of phenolic groups for the active compounds described above.
• Sulfates can be readily prepared by the reaction of the free phenolic compounds with sulfur trioxide complexed with an amine such as pyridine, trimethylamine, triethylamine, etc.
• Sulfamates can be prepared by treating the free phenolic compound with the desired amino or alkylamino or dialkylamino sulfamyl chloride in the presence of a suitable base such as pyridine.
• Sulfate esters can be prepared by reaction of the free phenol with the desired alkanesulfonyl chloride in the presence of a suitable base such as pyridine.
• this invention includes compounds containing phosphates at the phenol as well as dialkyl phosphates.
• Phosphates can be prepared by reaction of the phenol with the appropriate chlorophosphate.
• the dialkylphosphates can be hydrolyzed to yield the free phosphates.
• Phosphinates are also claimed where the phenol is reacted with the desired dialkylphosphinic chloride to yield the desired dialkylphosphinate of the phenol.
• the invention includes acceptable salt forms of these compounds formed from the addition reaction with either inorganic or organic acids.
• Inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid useful as well as organic acids such as acetic acid, propionic acid, citric acid, maleic acid, malic acid, tartaric acid, phthalic acid, succinic acid, methanesulfonic acid, toluenesulfonic acid, napthalenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid are useful.
• this invention includes quaternary ammonium salts of the compounds herein. These can be prepared by reacting the nucleophilic amines of the side chain with a suitably reactive alkylating agent such as an alkyl halide or benzyl halide.
• the present invention includes formulations utilizing a first subset or subgroup of compounds of the formulas III or IV, below:
• variable substituents including R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n, X, and Y are as defined above, or a pharmaceutically acceptable salt thereof.
• R 1 is selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, benzyloxy, or halogen;
• R 2 , R 3 , R 5 , and R 6 are independently selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, halogen, cyano, C 1 -C 6 alkyl, or trihalomethyl, preferably trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH;
• R 4 is selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, benzyloxy, halogen, cyano, C 1 -C 6 alkyl, or trihalomethyl;
• X is selected from H, C 1 -C 6 alkyl, cyano, nitro, trifluoromethyl, halogen;
• R 7 and R 8 are selected independently from H, C 1 -C 6 alkyl, or combined by —(CH 2 )p—, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, —CO 2 H, —CN, —CONH(C 1 -C 4 ), —NH 3 , C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, —NHSO 2 (C 1 -C 4 ), —NHCO(C 1 -
• the rings formed by a concatenated R 7 and R 8 may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
• the most preferred compounds of this first subset of compounds are those having the structural formulas I or II, above, wherein R 1 is OH; R 2 -R 6 are as defined above; X is selected from the group of Cl, NO 2 , CN, CF 3 , or CH 3 ; and Y is the moiety
• R 7 and R 8 are concatenated together as —(CH 2 ) r —, wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, —CO 2 H, —CN, —CONH(C 1 -C 4 )alkyl, —NH 2 , C 1 -C 4 alkylamino, di(C 1 -C 4 )alkylamino, —NHSO 2 (C 1 -C 4 )alkyl, NHCO(C 1 -C 4 )alkyl,
• the compounds of this first subset or subgroup of compounds can be produced by the methods described in EP 0 802 183 A1, published Oct. 22, 1997, and U.S. Pat. No. 5,780,497, the subject matter of which is incorporated herein by reference, or by other methods known in the art.
• Aryloxy-alkyl-dialkylamines or aryloxy-alkyl-cyclic amines useful as intermediates in the production of the compounds above can be produced and used as disclosed in WO 99/19293, published Apr. 22, 1999, the subject matter of which is also incorporated herein by reference.
• a second subset or subgroup of compounds useful with the formulations of this invention includes those of formulas (V) or (VI), below:
• variable substituents including R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n, X, and Y are as defined above, or a pharmaceutically acceptable salt thereof.
• a third subset of compounds useful with the present invention include those of the formulae VII and VIII:
• n 1, 2 or 3 and the variable substituents including R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n, X, and Y are as defined above, or a pharmaceutically acceptable salt thereof.
• the compounds of this third subset or subgroup of compounds can be produced by the methods described in U.S. Pat. No. 5,880,137 (Miller et al.), which is incorporated herein by reference, or by other methods known in the art.
• R 1 is selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, halogen;
• R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from H, OH or the C 1 -C 12 esters or alkyl ethers thereof, halogen, cyano, C 1 -C 6 alkyl, or trihalomethyl, preferably trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH;
• X is selected from H, C 1 -C 6 alkyl, cyano, nitro, trifluoromethyl, halogen;
• R 7 and R 8 are selected independently from H, C 1 -C 6 alkyl, or combined by —(CH2)p—, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, —CO 2 H, —CN, —CONH(C 1 -C 4 ), —NH 3 , C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, —NHSO 2 (C 1 -C 4 ), —NHCO(C 1 -C 4 ),
• the rings formed by a concatenated R 7 and R 8 may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
• the most preferred compounds of the present invention are those having the structural formulas I through VIII, above, wherein R 1 is OH; R 2 -R 6 are as defined above; X is selected from the group of Cl, NO 2 , CN, CF 3 , or CH 3 ; and Y is the moiety
• R 7 and R 8 are concatenated together as —(CH 2 ) r —, wherein r is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, —CO 2 H, —CN, —CONH(C 1 -C 4 )alkyl, —NH 2 , C 1 -C 4 alkylamino, di(C 1 -C 4 )alkylamino, -NHSO2(C 1 -C 4 )alkyl, NHCO(C 1 -C 4 )alkyl,
• R 7 and R 8 are concatenated together as —(CH 2 )p—, wherein p is an integer of from 2 to 6, preferably 4 to 6, the ring so formed is optionally substituted with 1-3 substituents selected from a group containing C 1 -C 3 alkyl, trifluoromethyl, halogen, hydrogen, phenyl, nitro, —CN.
• Aryloxy-alkyl-dialkylamine intermediates useful in preparing the substituted indole compounds of this invention can be synthesized as described in WO 99/19293 (Raveendranath et al.), which is incorporated herein by reference.
• compositions may be given at an effective dose of from about 0.1 mg/day to about 1,000 mg/day.
• administration will be from about 10 mg/day to about 600 mg/day in a single dose or in two or more divided doses. More preferably, administration will be from about 1 mg/day to about 200 mg/day in a single dose or in two or more divided doses. It will also be understood that these methods and regimens may be completed either remedially or prophylactically in the treatment, prohibition, inhibition or alleviation of the causes and symptoms of the maladies in question.
• the active ingredient in the formulations and methods of this invention is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, also known as TSE-424, or a pharmaceutically acceptable salt thereof
• the preferred daily dosage for oral delivery is from about 0.1 to about 50 mg, preferably from about 2.5 to about 40 mg per day.
• the active ingredient in the formulations and methods of this invention is 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol, also known as ERA-923, or a pharmaceutically acceptable salt form thereof
• the preferred daily dosage for oral delivery is from about 0.1 to about 200 mg, preferably from about 2.5 to about 100 mg per day.
• Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral suspensions.
• Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
• Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar.
• Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s).
• active pharmacological agents of this invention are 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol, also known as TSE-424, and 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol, also known as ERA-923, or a pharmaceutically acceptable salt of TSE-424 or ERA-923.
• formulations of this invention are pharmaceutical formulations containing a pharmaceutically effective amount of an active pharmacological agent and a carrier or excipient system comprising:
• a filler and disintegrant component comprising between about 50% and about 87% of the formulation, with from about 4% to about 40% of the formulation comprising one or more disintegrant agents;
• a glidant comprising between about 0.1% and about 5.5% of the formulation.
• the percentages listed in the formulations above indicate percentages by weight of the total weight of the components listed from a) to d).
• the formulations above also preferably contain an optional antioxidant component, preferably ascorbic acid, at a concentration of from about 0.5% to about 5.5% by weight of the formulation.
• the formulations are also preferably contained within a pharmaceutically acceptable capsule, such as a gel capsule, or coated with a film coating comprising from about 0.3% to about 8% by weight of the formulation.
• This invention also comprises a pharmaceutical carrier or excipient systems useful in pharmaceutical compositions utilizing as an active ingredient one or more of the compounds described herein, or a pharmaceutically acceptable salt thereof, as described herein.
• These pharmaceutical carrier or excipient systems comprise, by weight:
• a filler and disintegrant component comprising between about 54% and about 80% of the formulation, with the disintegrant agent(s) therein comprising from about 4% to about 40% by weight of the overall formulation;
• a wetting agent comprising between about 0.55% and about 2.5% of the formulation
• a glidant comprising between about 0.1% and about 5.0% of the formulation.
• the more preferred carrier or excipient systems above also optionally and preferably contain an antioxidant component, preferably ascorbic acid, at a concentration of from about 0.5% to about 5.0% by weight.
• an antioxidant component preferably ascorbic acid
• carrier or excipient systems of this invention are those comprising:
• a filler and disintegrant component as described above, comprising between about 50% and about 87% of the formulation, the disintegrant(s) therein comprising from about 25% to about 35% of the formulation, by weight;
• a lubricant comprising between about 0.2% and about 5.5% of the formulation
• a glidant comprising between about 0.1% and about 5.5% of the formulation
• carrier or excipient systems herein may also be used as described to produce comparable pharmaceutical compositions or formulations containing other non-steroidal estrogenic agents, such as raloxifene, tamoxifen, droloxifene, arzoxifene or CP 336156 and/or an analog of these compounds, or a pharmaceutically acceptable salt of the compounds or their analogs, as an active pharmacological agent.
• non-steroidal estrogenic agents such as raloxifene, tamoxifen, droloxifene, arzoxifene or CP 336156 and/or an analog of these compounds, or a pharmaceutically acceptable salt of the compounds or their analogs, as an active pharmacological agent.
• the raloxifene-containing compositions of this invention may be administered with raloxifene being given at a daily dose of from about 0.1 mg to about 1,000 mg, as a single daily unit dose or administered in two or more doses over the course of the day. More preferably, the daily unit doses of these compositions will comprise a dose of raloxifene or its salt form at from about 50 mg to about 400 mg, more preferably from about 50 mg to about 200 mg.
• a specifically preferred raloxifene formulation herein may comprise a carrier or excipient system of this invention and raloxifene, or a pharmaceutically acceptable salt thereof, at a pharmaceutically effective dose of from about 55 mg to about 150 mg or from about 60 mg to about 150 mg.
• TSE-424 used mg mg of film coat applied/tablet c 1 mg 1% 100 6.0 2.5 mg 1% 250 10.0 5 mg 5% 100 6.0 10 mg 5% 200 8.0 20 mg 5% 400 13.0 c
• the film coating suspension is made using White Opadry II (YS-30-18105) and Purified Water
• Wet granulation of the formulations as described in Table 1 may be carried out by mixing the drug and ascorbic acid with a portion of the lactose, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate.
• the sodium lauryl sulfate is dissolved in the water and used to granulate the mixture of powders in a high shear mixer.
• the granulation is dried in a fluid bed dryer to a moisture of 2-3%.
• the particle size of the dried granulation is controlled by passing through a mill equipped with knife-edged blades and using a 20- or 30-mesh screen.
• the silicon dioxide and remaining lactose, microcrystalline cellulose, pregelatinized starch, and sodium starch glycolate are mixed with the milled granulation in a tumble-type mixer.
• the final blend is prepared by adding magnesium stearate to the tumble-type mixer and mixing. Compression is carried out on a rotary tablet press using appropriate size tooling. Coating is performed in conventional coating pans and applying the coating suspension to achieve a suitable film coat.
• Formulations of this invention containing 1% active ingredient were prepared for stability comparison of formulations with and without ascorbic acid present over periods of 1, 3 and 6 months at either 25° C. and 60% relative humidity (RH) or 40° C. and 75% relative humidity.
• RH 60% relative humidity
• TSE-424 ascorbic acid component provided protection of the estrogenic agent (TSE-424) versus oxidation in solid dosage formulations.
• a preferred carrier or excipient system for formulating a granulation of from about 2 to about 8% by weight of one of the active pharmacological agents of this invention, preferably about 5%, may be produced utilizing the carrier or excipient components on a weight percentage; lactose from about 32% to about 38%, microcrystalline cellulose from about 32% to about 38%, pregelatinized starch from about 12% to about 16%, ascorbic acid from about 1% to about 2%, sodium lauryl sulfate from about 1% to about 2%, sodium starch glycolate from about 4% to about 8%, silicon dioxide from about 0.1% to about 0.2% and magnesium stearate from about 0.3% to about 0.7%.
• a formulation of this invention utilizing TSE-424 as the active ingredient at a 5% granulation was prepared utilizing the components listed below in a granulation part of components and a dry part.
• Item No. Ingredients Mg/Unit Granulation Part: 1 TSE-424 acetate 5.00 2 Lactose NF 26.60 3 Microcrystalline Cellulose NF 25.00 4 Pregelatinized Starch NF 10.00 5 Ascorbic Acid USP 1.50 6 Sodium Lauryl Sulfate NF 1.50 7 Sodium Starch Glycolate NF 4.00 8 Water, Purified USP Q.S.
• formulations of this invention may be produced with a carrier or excipient system utilizing the components of Examples 7 through 9.
• the percentages listed below represent the weight percentage of each component to the overall weight of the excipient or carrier system.
• Each formulation may then be formed into tablets, spheroids or other solid dosage forms of the desired size and coated as described herein.
• These formulations include those comprising raloxifene HCl as an active pharmacological agent at the unit doses described above, specifically including unit doses of 50 mg, 60 mg, 75 mg, 100 mg and 150 mg.
• Example 7 lactose 35% microcrystalline cellulose 34% starch 20% sodium lauryl sulfate 2% magnesium stearate 1 % talc 6.5% ascorbic acid 1.5%
• Example 8 microcrystalline cellulose 50% sucrose 20% sodium starch glycolate 9.8% powdered cellulose 5% sorbitan monolaurate 5% calcium stearate 8% silicon dioxide 0.2% sodium ascorbate 2%
• Example 9 mannitol 45.5% microcrystalline cellulose 25% polyoxyol 20 cetostaryl ether 5% crospovidone 4% stearic acid 10% calcium silicate 0.5% ascorbic acid 10%
• Maintaining a low moisture content in the dried granulation compositions and the final products of this invention also enhances the stability of the resulting compositions.

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=22806095

Family Applications (2)

Family Applications After (1)

Country Status (26)

Cited By (11)

Families Citing this family (30)

Citations (2)

Family Cites Families (19)

• 2001
  • 2001-06-28 AR ARP010103094A patent/AR029538A1/es not_active Application Discontinuation
  • 2001-06-29 KR KR1020077025013A patent/KR100894027B1/ko not_active IP Right Cessation
  • 2001-06-29 KR KR1020037000072A patent/KR100862174B1/ko not_active IP Right Cessation
  • 2001-06-29 CN CNA2008101697811A patent/CN101416949A/zh active Pending
  • 2001-06-29 AU AU7174101A patent/AU7174101A/xx active Pending
  • 2001-06-29 MX MXPA02012891A patent/MXPA02012891A/es active IP Right Grant
  • 2001-06-29 AU AU2001271741A patent/AU2001271741B2/en not_active Ceased
  • 2001-06-29 EP EP01950781A patent/EP1309327B1/en not_active Expired - Lifetime
  • 2001-06-29 PT PT01950781T patent/PT1309327E/pt unknown
  • 2001-06-29 CN CN01815086A patent/CN1450895A/zh active Pending
  • 2001-06-29 JP JP2002508441A patent/JP2004502733A/ja active Pending
  • 2001-06-29 IL IL15364701A patent/IL153647A0/xx active IP Right Grant
  • 2001-06-29 WO PCT/US2001/020993 patent/WO2002003987A2/en active IP Right Grant
  • 2001-06-29 EA EA200300122A patent/EA006386B1/ru not_active IP Right Cessation
  • 2001-06-29 NZ NZ523330A patent/NZ523330A/en unknown
  • 2001-06-29 ES ES01950781T patent/ES2336304T3/es not_active Expired - Lifetime
  • 2001-06-29 BR BR0112242-8A patent/BR0112242A/pt not_active Application Discontinuation
  • 2001-06-29 US US09/896,226 patent/US20020031548A1/en not_active Abandoned
  • 2001-06-29 SI SI200130959T patent/SI1309327T1/sl unknown
  • 2001-06-29 DE DE60140945T patent/DE60140945D1/de not_active Expired - Lifetime
  • 2001-06-29 AT AT01950781T patent/ATE453391T1/de not_active IP Right Cessation
  • 2001-06-29 PL PL365875A patent/PL204866B1/pl not_active IP Right Cessation
  • 2001-06-29 CA CA002415058A patent/CA2415058A1/en not_active Abandoned
  • 2001-06-29 HU HU0301422A patent/HUP0301422A3/hu unknown
  • 2001-06-29 DK DK01950781.3T patent/DK1309327T3/da active
  • 2001-07-04 TW TW090116358A patent/TWI294777B/zh active
• 2002
  • 2002-12-25 IL IL153647A patent/IL153647A/en not_active IP Right Cessation
• 2003
  • 2003-01-03 NO NO20030030A patent/NO20030030L/no not_active Application Discontinuation
  • 2003-02-05 ZA ZA200301004A patent/ZA200301004B/en unknown
• 2007
  • 2007-11-20 US US11/943,269 patent/US7759386B2/en not_active Expired - Fee Related
• 2010
  • 2010-03-19 CY CY20101100249T patent/CY1109915T1/el unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events